Publications en collaboration avec des chercheurs de Yale School of Medicine (9)

2022

  1. Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy

    British Journal of Clinical Pharmacology, Vol. 88, Núm. 7, pp. 3182-3192

  2. Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial

    European Journal of Cancer, Vol. 160, pp. 61-71

  3. Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

    Journal for immunotherapy of cancer, Vol. 10, Núm. 8

2021

  1. Enfortumab vedotin in previously treated advanced urothelial carcinoma

    New England Journal of Medicine, Vol. 384, Núm. 12, pp. 1125-1135

2020

  1. Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial

    Bladder Cancer, Vol. 6, Núm. 1, pp. 43-52

  2. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

    The Lancet Oncology, Vol. 21, Núm. 1, pp. 105-120

2017

  1. Borealis-1: A randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer

    Annals of Oncology, Vol. 28, Núm. 10, pp. 2481-2488

  2. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

    The Lancet, Vol. 390, Núm. 10109, pp. 2266-2277

  3. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97